ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 744

Longitudinal Assessment of Th1 and Th2 Cytokines: A Comparison Between Adult-Onset and Childhood-Onset Systemic Lupus Erythematous

Karina Pelicari1, Mariana Postal1, Nailu A. Sinicato2, Fernando A. Peres1, Roberto Marini Sr.3, Lilian Tereza Costallat4 and Simone Appenzeller5, 1Medicine, State University of Campinas, Campinas, Brazil, 2Pediatrics, State University of Campinas, Campinas, Brazil, 3Pediatric Rheumatology Unit, State University of Campinas, São Paulo, Brazil, 4RUA EZEQUIEL MAGALHAES,26, Unicamp, Campinas, Brazil, 5Division of Rheumatology, Faculty of Medical Science, State University of Campinas, São Paulo, Brazil

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Clinical, interleukins (IL) and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The clinical presentation may be different between adult-onset SLE (aSLE) and childhood-onset SLE (cSLE). The profile of cytokine may the clarify of SLE pathophysiology. The aim of this study was to determine the serum levels of Th1 (IL-12), Th2 (IL-6 e IL-10) longitudinally as well as its possible associations in aSLE and cSLE. 

Methods:

The included SLE patients were recruited from outpatient Rheumatology and Pediatric Rheumatology –State University of Campinas, matched for disease duration. Sera samples were obtained quarterly from all participants, in each routine visit we made a blood collection, totaling four different periods in all patients, in the absence of infections. We further assessed disease activity through of the SLE Disease Activity Index (SLEDAI) and damage through Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI), mood and anxiety through Becks Depression (BDI) and Anxiety Inventory (BAI) and current drug exposures. Th1 (IL-12), Th2 (IL-6 and IL-10) cytokines levels were measured by ELISA using commercial kits. Data were compared by non-parametric tests.

Results:

We included 63 cSLE patients (mean age 19.7±4.3 and disease duration 7.35±4.22), 67 aSLE patients (mean age 39.9±11.8 and disease duration 7.73±3.18) and 40 healthy controls (mean age 29.6±10). In aSLE patients compared with healthy controls during the four periods evaluated, IL-6 levels were significantly increased in patients (p=0.03, p=0.003, p=0.002, p=0.002), IL-12 fluctuated during the period evaluated (p=0.75, p=0.50, p=0.01, p=0.001) and IL-10 It had no significant difference (p=0.32, p=0.13, p=0.99, p=0.08).  In cSLE patients compared with healthy controls, we observed a significantly increase of IL-12 (p=0.04, p=0.001, p=0.01, p=0.02), we did not observe significant difference in IL-10 (p=0.94, p=0.85, p=0.81, p=0.95) and IL-6 (p=0.66, p=0.14, p=0.25, p=0.21). Comparing the levels of cytokines between aSLE and cSLE, we observed that IL-12 fluctuated during the period evaluated (p=0.07, p=0.001, p=0.99, p=0.14) and had no significant difference in IL-6 (p=0.97, p=0.11, p=0.15, p=0.53) and IL-10 (p=0.09, p=0.29, p=0.59, p=0.25). We did not observe an association between disease activity and cytokines in any period (p>0.05). The aSLE patients had a significant decrease of disease activity indices during periods evaluated (p=0.021), There was no significant difference in disease activity among cSLE and aSLE patients (p>0.05). No significant difference in SDI scores between aSLE and cSLE (p=0.10). Regarding medication, we observed that aSLE (p=0.001) and cSLE (p=0.001) patients had a significant decrease of use of prednisone during the four periods. In disorders of mood and anxiety, during the four evaluated periods, no significant variation in BAI, cSLE (p=0.52) and aSLE (p=0.13), and BDI, cSLE (p=0.29) and aSLE (p=0.65) was observed. When comparing the patients we observed that aSLE have significantly higher scores of BDI (p≤0.002) and BAI (p≤0.006) than cSLE.

Conclusion:

Cytokines behave differently in aSLE and cSLE patients. The analyzed cytokines fluctuated throughout the study period, however were not associated with disease activity markers.


Disclosure: K. Pelicari, None; M. Postal, None; N. A. Sinicato, None; F. A. Peres, None; R. Marini Sr., None; L. T. Costallat, None; S. Appenzeller, None.

To cite this abstract in AMA style:

Pelicari K, Postal M, Sinicato NA, Peres FA, Marini R Sr., Costallat LT, Appenzeller S. Longitudinal Assessment of Th1 and Th2 Cytokines: A Comparison Between Adult-Onset and Childhood-Onset Systemic Lupus Erythematous [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/longitudinal-assessment-of-th1-and-th2-cytokines-a-comparison-between-adult-onset-and-childhood-onset-systemic-lupus-erythematous/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinal-assessment-of-th1-and-th2-cytokines-a-comparison-between-adult-onset-and-childhood-onset-systemic-lupus-erythematous/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology